These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32415846)

  • 1. Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial.
    Boulware DR; Nalintya E; Rajasingham R; Kirumira P; Naluyima R; Turya F; Namanda S; Rutakingirwa MK; Skipper CP; Nikweri Y; Hullsiek KH; Bangdiwala AS; Meya DB
    Med Mycol; 2020 Nov; 58(8):1037-1043. PubMed ID: 32415846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.
    Rhein J; Morawski BM; Hullsiek KH; Nabeta HW; Kiggundu R; Tugume L; Musubire A; Akampurira A; Smith KD; Alhadab A; Williams DA; Abassi M; Bahr NC; Velamakanni SS; Fisher J; Nielsen K; Meya DB; Boulware DR;
    Lancet Infect Dis; 2016 Jul; 16(7):809-818. PubMed ID: 26971081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
    Rhein J; Huppler Hullsiek K; Tugume L; Nuwagira E; Mpoza E; Evans EE; Kiggundu R; Pastick KA; Ssebambulidde K; Akampurira A; Williams DA; Bangdiwala AS; Abassi M; Musubire AK; Nicol MR; Muzoora C; Meya DB; Boulware DR;
    Lancet Infect Dis; 2019 Aug; 19(8):843-851. PubMed ID: 31345462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
    Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
    Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
    Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.
    Katende A; Mbwanji G; Faini D; Nyuri A; Kalinjuma AV; Mnzava D; Hullsiek KH; Rhein J; Weisser M; Meya DB; Boulware DR; Letang E;
    Mycoses; 2019 Dec; 62(12):1127-1132. PubMed ID: 31461550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
    McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
    Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
    Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
    AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.
    Wake RM; Britz E; Sriruttan C; Rukasha I; Omar T; Spencer DC; Nel JS; Mashamaite S; Adelekan A; Chiller TM; Jarvis JN; Harrison TS; Govender NP
    Clin Infect Dis; 2018 Feb; 66(5):686-692. PubMed ID: 29028998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing deaths from cryptococcal meningitis: from bench to bedside.
    Roy M; Chiller T
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):715-7. PubMed ID: 21905781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluconazole monotherapy for cryptococcosis in non-AIDS patients.
    Yamaguchi H; Ikemoto H; Watanabe K; Ito A; Hara K; Kohno S
    Eur J Clin Microbiol Infect Dis; 1996 Oct; 15(10):787-92. PubMed ID: 8950555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
    Lofgren S; Abassi M; Rhein J; Boulware DR
    Expert Rev Anti Infect Ther; 2017 Apr; 15(4):331-340. PubMed ID: 28111998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.